Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, shared a post on LinkedIn:
“It was a privilege to serve as scientific Co‑Chair of ESMO – European Society for Medical Oncology Targeted Anticancer Therapies (TAT) this week in Paris.
ESMO‑TAT, where first‑in‑human and early‑phase oncology research takes center stage, brings together scientists, clinicians, regulators, and industry leaders around one shared goal: accelerating the translation of early research into meaningful options for patients.
Across three days of rigorous science and open dialogue, I was encouraged by the quality of the data, the depth of discussion, and the collaborative spirit shaping the next generation of cancer therapies. Hot topics like innovation through AI and digital solutions were core to the discussion.
Thank you to my fellow co‑chairs, Elena Garralda Cabanas and Carlos Gomez-Roca; ESMO president Fabrice Andre, ESMO President‑Elect Giuseppe Curigliano and European Neuroendocrine Tumor Society e.V. (ENETS) Chair‑Elect Nicola Fazio; and the ESMO team for an exceptional congress. This community continues to push the boundaries of what’s possible in early clinical development.”
Other articles featuring Cristian Massacesi on OncoDaily.
